<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345929</url>
  </required_header>
  <id_info>
    <org_study_id>7625A-005</org_study_id>
    <secondary_id>CXA-cUTI-10-04</secondary_id>
    <secondary_id>CXA-cUTI-10-05</secondary_id>
    <nct_id>NCT01345929</nct_id>
    <nct_alias>NCT01345955</nct_alias>
  </id_info>
  <brief_title>Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of
      CXA 201 IV infusions (1500 mg q8h) versus levofloxacin IV infusions (750 mg qd) for the
      treatment of adults with a cUTI (including pyelonephritis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 500 subjects will be enrolled into this study and randomized 1:1 to receive
      CXA-201 or comparator (levofloxacin) resulting in 250 subjects per treatment arm. Subject
      participation will require a minimum commitment of 35 days and a maximum of 42 days. Subjects
      will be hospitalized for the administration of all doses of IV study therapy. A test of cure
      visit will occur at 7 days after the last dose of study drug and a late follow-up evaluation
      or contact will occur a minimum of 28 days and a maximum of 35 days after the last dose of
      study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2011</start_date>
  <completion_date type="Actual">September 1, 2013</completion_date>
  <primary_completion_date type="Actual">August 1, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Modified ITT (mMITT) Population</measure>
    <time_frame>Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the TOC Visit in the Microbiologically Evaluable (ME) Population.</measure>
    <time_frame>Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">558</enrollment>
  <condition>Complicated Urinary Tract Infection</condition>
  <condition>Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>CXA-201 as treatment for cUTI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CXA-201 IV infusion (1500mg q8) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin as treatment for cUTI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin IV infusion (750mg qd) for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXA-201</intervention_name>
    <description>CXA-201 IV infusion (1500mg q8) for 7 days</description>
    <arm_group_label>CXA-201 as treatment for cUTI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin IV infusion (750mg qd) for 7 days</description>
    <arm_group_label>Levofloxacin as treatment for cUTI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent prior to any study-related procedure not part of
             normal medical care (a legally acceptable representative may provide consent if the
             subject is unable to do so, provided this is approved by local country and institution
             specific guidelines).

          2. Be males or females ≥ 18 years of age

          3. If female, subject is non-lactating, and is either:

               1. Not of childbearing potential, defined as postmenopausal for at least 1 year or
                  surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy; or

               2. Of childbearing potential and is practicing a barrier method of birth control
                  (e.g., a diaphragm or contraceptive sponge) along with 1 of the following
                  methods: oral or parenteral contraceptives (for 3 months prior to study drug
                  administration), or a vasectomized partner. Or, subject is practicing abstinence
                  from sexual intercourse. Subjects must be willing to practice these methods for
                  the duration of the trial and for at least 35 days after last dose of study
                  medication.

          4. Males are required to practice reliable birth control methods (condom or other barrier
             device) during the conduct of the study and for at least 35 days after last dose of
             study medication.

          5. Pyuria (white blood cell [WBC] count &gt; 10/μL in unspun urine or ≥ 10 per high power
             field in spun urine).

          6. Clinical signs and/or symptoms of cUTI, either of:

               1. Pyelonephritis, as indicated by at least 2 of the following:

                    -  Documented fever (oral temperature &gt; 38°C) accompanied by patient symptoms
                       of rigors, chills, or &quot;warmth&quot;;

                    -  Flank pain;

                    -  Costovertebral angle tenderness or suprapubic tenderness on physical exam;
                       or

                    -  nausea or vomiting; OR

               2. Complicated lower UTI, as indicated by at least 2 of the following:

                    -  At least 2 of the following new or worsening symptoms of cUTI:

                         -  Dysuria; urinary frequency or urinary urgency;

                         -  Documented fever (oral temperature &gt; 38°C) accompanied by patient
                            symptoms of rigors, chills, or &quot;warmth&quot;;

                         -  Suprapubic pain or flank pain;

                         -  Costovertebral angle tenderness or suprapubic tenderness on physical
                            exam; or

                         -  Nausea or vomiting; plus,

                    -  At least 1 of the following complicating factors:

                         -  Males with documented history of urinary retention;

                         -  Indwelling urinary catheter that is scheduled to be removed during IV
                            study therapy and before the EOT;

                         -  Current obstructive uropathy that is scheduled to be medically or
                            surgically relieved during IV study therapy and before the EOT; or

                         -  Any functional or anatomical abnormality of the urogenital tract
                            (including anatomic malformations or neurogenic bladder) with voiding
                            disturbance resulting in at least 100 mL residual urine.

          7. Have a pretreatment baseline urine culture specimen obtained within 24 hours before
             the start of administration of the first dose of study drug.

             NOTE: Subjects may be enrolled in this study and start IV study drug therapy before
             the Investigator knows the results of the baseline urine culture.

          8. Require IV antibacterial therapy for the treatment of the presumed cUTI.

        Exclusion Criteria:

          1. Have a documented history of any moderate or severe hypersensitivity or allergic
             reaction to any β-lactam or quinilone antibacterial (Note: for β-lactams, a history of
             a mild rash followed by uneventful re-exposure is not a contraindication to
             enrollment)

          2. Have a concomitant infection at the time of randomization, which requires non-study
             systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only
             gram-positive activity [e.g., vancomycin, linezolid] are allowed.)

          3. Receipt of any amount of potentially therapeutic antibacterial therapy after
             collection of the pretreatment baseline urine culture and before administration of the
             first dose of study drug.

          4. Receipt of any dose of a potentially therapeutic antibacterial agent for the treatment
             of the current UTI within 48 hours before the study-qualifying pretreatment baseline
             urine is obtained (exceptions: subjects with an active cUTI who have received prior
             antibiotics may be enrolled provided a minimum of 48 hours have elapsed between the
             last dose of the prior antibiotic and the time of obtaining the baseline urine
             specimen. Subjects receiving current antibiotic prophylaxis for cUTI who present with
             signs and symptoms consistent with an active new cUTI may be enrolled provided all
             other eligibility criteria are met including obtaining a pre-treatment qualifying
             baseline urine culture).

          5. Intractable urinary infection at baseline that the Investigator anticipates would
             require more than 7 days of study drug therapy.

          6. Complete, permanent obstruction of the urinary tract.

          7. Confirmed fungal urinary tract infection at time of randomization (with ≥ 103 fungal
             CFU/mL).

          8. Permanent indwelling bladder catheter or urinary stent including nephrostomy.

          9. Suspected or confirmed perinephric or intrarenal abscess.

         10. Suspected or confirmed prostatitis.

         11. Ileal loop or known vesico-ureteral reflux.

         12. Severe impairment of renal function including an estimated CrCl &lt; 30 mL/min,
             requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (&lt; 20
             mL/h urine output over 24 hours).

         13. Current urinary catheter that is not scheduled to be removed before the EOT
             (intermittent straight catheterization during the IV study drug administration period
             is acceptable).

         14. Any condition or circumstance that, in the opinion of the Investigator, would
             compromise the safety of the subject or the quality of study data.

         15. Any rapidly progressing disease or immediately life-threatening illness including
             acute hepatic failure, respiratory failure, and septic shock.

         16. Immunocompromising condition, including established AIDS, hematological malignancy, or
             bone marrow transplantation, or immunosuppressive therapy including cancer
             chemotherapy, medications for prevention of organ transplantation rejection, or the
             administration of corticosteroids equivalent to or greater than 40 mg of prednisone
             per day administered continuously for more than 14 days preceding randomization.

         17. One or more of the following laboratory abnormalities in baseline specimens: aspartate
             aminotransferase (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), alkaline
             phosphatase, or total bilirubin level greater than 3 times the upper limit of normal
             (ULN), absolute neutrophil count less than 500/μL, platelet count less than 40,000/μL,
             or hematocrit less than 20%.

         18. Participation in any clinical study of an investigational product within 30 days prior
             to the proposed first day of study drug.

         19. Previous participation in any study of CXA-101 or CXA-201.

         20. Women who are pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Obiamiwe Umeh, M.D., MSc.</last_name>
    <role>Study Director</role>
    <affiliation>Cubist Pharmaceuticals LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande de Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Jose de Rio Preto</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Armenia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kohtla-Jarve</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilsi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubeck</city>
        <state>Schleswig-Holstein</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyor</city>
        <state>Budapest</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szentes</city>
        <state>Csongrad</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sopron</city>
        <state>Gyor-moson-sopron</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salgotarjan</city>
        <state>Nograd</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyiregyhaza</city>
        <state>Szabolcs-Szatmar-Bereg</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <state>Zala</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tatabánya</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <state>Sharon</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <state>Teah Tiqwa</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Hashomer</city>
        <state>Tel Aviv</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ventspills</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veracruz</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oradea</city>
        <state>Bihor</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penza</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Levice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skalica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middleburg</city>
        <state>Mpumalanga</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellville</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakorn Ratchasima</city>
        <state>Nakhon Ratchasima</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lop Buri</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prachuap Khiri Khan</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <results_first_submitted>January 9, 2015</results_first_submitted>
  <results_first_submitted_qc>January 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 15, 2015</results_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cUTI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two P3 protocols were initiated (NCT01345929 and NCT01345955) subsequently, Cubist and FDA agreed that integrated data from the 2 protocols could be analyzed and reported in a single Clinical Study Report. A total of 1083 subjects were randomized to both arms, 558 to NCT01345929 and 525 to NCT01345955. Of these, 552 and 516 received treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CXA-201 as Treatment for cUTI</title>
          <description>CXA-201 IV infusion (1500mg q8) for 7 days
CXA-201: CXA-201 IV infusion (1500mg q8) for 7 days
Of the 1083 subjects in the integrated analysis set, 533 received CXA.</description>
        </group>
        <group group_id="P2">
          <title>Levofloxacin as Treatment for cUTI</title>
          <description>Levofloxacin IV infusion (750mg qd) for 7 days
Levofloxacin: Levofloxacin IV infusion (750mg qd) for 7 days
Of the 1083 subjects in the integrated analysis set, 535 received levofloxacin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="533"/>
                <participants group_id="P2" count="535"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="512"/>
                <participants group_id="P2" count="516"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Didn't meet eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>40,000 CFU/ML</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CXA-201 as Treatment for cUTI</title>
          <description>CXA-201 IV infusion (1500mg q8) for 7 days
CXA-201: CXA-201 IV infusion (1500mg q8) for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Levofloxacin as Treatment for cUTI</title>
          <description>Levofloxacin IV infusion (750mg qd) for 7 days
Levofloxacin: Levofloxacin IV infusion (750mg qd) for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="533"/>
            <count group_id="B2" value="535"/>
            <count group_id="B3" value="1068"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.7" spread="19.52"/>
                    <measurement group_id="B2" value="48.6" spread="20.05"/>
                    <measurement group_id="B3" value="49.1" spread="19.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="374"/>
                    <measurement group_id="B2" value="380"/>
                    <measurement group_id="B3" value="754"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Modified ITT (mMITT) Population</title>
        <time_frame>Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration)</time_frame>
        <population>mMITT: Treated subjects, with baseline pathogen.</population>
        <group_list>
          <group group_id="O1">
            <title>CXA-201 as Treatment for cUTI</title>
            <description>CXA-201 IV infusion (1500mg q8) for 7 days
CXA-201: CXA-201 IV infusion (1500mg q8) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin as Treatment for cUTI</title>
            <description>Levofloxacin IV infusion (750mg qd) for 7 days
Levofloxacin: Levofloxacin IV infusion (750mg qd) for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Modified ITT (mMITT) Population</title>
          <population>mMITT: Treated subjects, with baseline pathogen.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower bound of the 2-sided 95% CI was greater than -10%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.31</ci_lower_limit>
            <ci_upper_limit>14.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the TOC Visit in the Microbiologically Evaluable (ME) Population.</title>
        <time_frame>Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration)</time_frame>
        <population>ME: Treated patients, with baseline pathogen, complied with protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>CXA-201 as Treatment for cUTI</title>
            <description>CXA-201 IV infusion (1500mg q8) for 7 days
CXA-201: CXA-201 IV infusion (1500mg q8) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin as Treatment for cUTI</title>
            <description>Levofloxacin IV infusion (750mg qd) for 7 days
Levofloxacin: Levofloxacin IV infusion (750mg qd) for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the TOC Visit in the Microbiologically Evaluable (ME) Population.</title>
          <population>ME: Treated patients, with baseline pathogen, complied with protocol.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower bound of the 2-sided 95% CI was greater than -10%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.95</ci_lower_limit>
            <ci_upper_limit>13.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CXA-201 as Treatment for cUTI</title>
          <description>CXA-201 IV infusion (1500mg q8) for 7 days
CXA-201: CXA-201 IV infusion (1500mg q8) for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Levofloxacin as Treatment for cUTI</title>
          <description>Levofloxacin IV infusion (750mg qd) for 7 days
Levofloxacin: Levofloxacin IV infusion (750mg qd) for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopaty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Emphysematous pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Renal tubular acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="535"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="535"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator(s) must undertake not to submit any part of the data from this protocol for publication without the prior consent of Cubist Pharmaceuticals, Inc.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two identical P3 protocols were initiated (NCT01345929 and NCT01345955) subsequently, Cubist and FDA agreed that integrated data from the 2 protocols could be analyzed and reported in a single Clinical Study Report. These analyses are presented here.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Obi Umeh, Vice President Global Medical Sciences</name_or_title>
      <organization>Cubist Pharmaceuticals, Inc.</organization>
      <phone>781-860-8415</phone>
      <email>obiamiwe.umeh@cubist.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

